564 related articles for article (PubMed ID: 22878500)
21. Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.
Lee SW; Youn H; Kim EJ; Um SJ
Mol Cell; 2013 Jul; 51(2):200-10. PubMed ID: 23850490
[TBL] [Abstract][Full Text] [Related]
22. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
23. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.
Machida YJ; Machida Y; Vashisht AA; Wohlschlegel JA; Dutta A
J Biol Chem; 2009 Dec; 284(49):34179-88. PubMed ID: 19815555
[TBL] [Abstract][Full Text] [Related]
24. Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Kadariya Y; Cheung M; Xu J; Pei J; Sementino E; Menges CW; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
Cancer Res; 2016 May; 76(9):2836-44. PubMed ID: 26896281
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
26. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
27. BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
Sahtoe DD; van Dijk WJ; Ekkebus R; Ovaa H; Sixma TK
Nat Commun; 2016 Jan; 7():10292. PubMed ID: 26739236
[TBL] [Abstract][Full Text] [Related]
28. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Kuznetsov JN; Aguero TH; Owens DA; Kurtenbach S; Field MG; Durante MA; Rodriguez DA; King ML; Harbour JW
Sci Adv; 2019 Sep; 5(9):eaax1738. PubMed ID: 31555735
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
31. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
Elife; 2021 Jun; 10():. PubMed ID: 34170818
[TBL] [Abstract][Full Text] [Related]
32. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
Asada S
Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis identifies novel binding partners of BAP1.
Baas R; J van der Wal F; Bleijerveld OB; van Attikum H; Sixma TK
PLoS One; 2021; 16(9):e0257688. PubMed ID: 34591877
[TBL] [Abstract][Full Text] [Related]
34. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
[TBL] [Abstract][Full Text] [Related]
35. Suppressive role of OGT-mediated O-GlcNAcylation of BAP1 in retinoic acid signaling.
Moon S; Lee YK; Lee SW; Um SJ
Biochem Biophys Res Commun; 2017 Oct; 492(1):89-95. PubMed ID: 28802580
[TBL] [Abstract][Full Text] [Related]
36. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1.
He M; Chaurushiya MS; Webster JD; Kummerfeld S; Reja R; Chaudhuri S; Chen YJ; Modrusan Z; Haley B; Dugger DL; Eastham-Anderson J; Lau S; Dey A; Caothien R; Roose-Girma M; Newton K; Dixit VM
Science; 2019 Apr; 364(6437):283-285. PubMed ID: 31000662
[TBL] [Abstract][Full Text] [Related]
38. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
39. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
40. BAP1 Missense Mutations in Cancer: Friend or Foe?
Okonska A; Felley-Bosco E
Trends Cancer; 2019 Nov; 5(11):659-662. PubMed ID: 31735283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
